The impact of immunosuppressive regimens on the cost of liver transplantation - Results from the U.S. FK506 multicenter trial

J. R. Lake, K. J. Gorman, C. O. Esquivel, R. H. Wiesner, G. B. Klintmalm, C. M. Miller, B. W. Shaw, J. A. Gordon

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

In an effort to determine the total one-year cost of liver transplantation, the underlying drivers of that cost, and any cost differences between alternative immunosuppressive regimens, an analysis was performed comparing the average one-year posttransplant charges of 322 patients participating in the 'U.S. Multi-center Prospective Randomized Trial Comparing FK-506 to Cyclosporine in Liver Transplantation.' Total one-year inpatient charges including all readmissions were examined. Professional fees and outpatient charges were excluded. Costs for tacrolimus drug and blood assays were assumed to be equal to those in the CsA group. For patients completing the study, the tacrolimus group bad an average length of stay and average one-year cost seven days (P=.06) and $19,290 (P=.05) lower than the CsA group. The difference in rejection profiles between the two arms seems to largely account for the lower costs. The tacrolimus arm consistently had fewer patients in the more severe rejection groups. Increased incidence and severity of rejection were directly related to higher average lengths of stay and costs of transplantation (P < .001). Tacrolimus immunosuppression during the first year after liver transplantation is more cost-effective than CsA in achieving similar patient and graft survival rates. Differing incidence and severity of rejection can dramatically affect the first-year cost of liver transplantation.

Original languageEnglish (US)
Pages (from-to)1089-1095
Number of pages7
JournalTransplantation
Volume60
Issue number10
StatePublished - 1995

Fingerprint

Tacrolimus
Immunosuppressive Agents
Liver Transplantation
Multicenter Studies
Costs and Cost Analysis
Length of Stay
Drug Costs
Fees and Charges
Incidence
Graft Survival
Immunosuppression
Cyclosporine
Inpatients
Outpatients
Survival Rate
Transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Lake, J. R., Gorman, K. J., Esquivel, C. O., Wiesner, R. H., Klintmalm, G. B., Miller, C. M., ... Gordon, J. A. (1995). The impact of immunosuppressive regimens on the cost of liver transplantation - Results from the U.S. FK506 multicenter trial. Transplantation, 60(10), 1089-1095.

The impact of immunosuppressive regimens on the cost of liver transplantation - Results from the U.S. FK506 multicenter trial. / Lake, J. R.; Gorman, K. J.; Esquivel, C. O.; Wiesner, R. H.; Klintmalm, G. B.; Miller, C. M.; Shaw, B. W.; Gordon, J. A.

In: Transplantation, Vol. 60, No. 10, 1995, p. 1089-1095.

Research output: Contribution to journalArticle

Lake, JR, Gorman, KJ, Esquivel, CO, Wiesner, RH, Klintmalm, GB, Miller, CM, Shaw, BW & Gordon, JA 1995, 'The impact of immunosuppressive regimens on the cost of liver transplantation - Results from the U.S. FK506 multicenter trial', Transplantation, vol. 60, no. 10, pp. 1089-1095.
Lake JR, Gorman KJ, Esquivel CO, Wiesner RH, Klintmalm GB, Miller CM et al. The impact of immunosuppressive regimens on the cost of liver transplantation - Results from the U.S. FK506 multicenter trial. Transplantation. 1995;60(10):1089-1095.
Lake, J. R. ; Gorman, K. J. ; Esquivel, C. O. ; Wiesner, R. H. ; Klintmalm, G. B. ; Miller, C. M. ; Shaw, B. W. ; Gordon, J. A. / The impact of immunosuppressive regimens on the cost of liver transplantation - Results from the U.S. FK506 multicenter trial. In: Transplantation. 1995 ; Vol. 60, No. 10. pp. 1089-1095.
@article{0d26a610af274c92a44925c15a057126,
title = "The impact of immunosuppressive regimens on the cost of liver transplantation - Results from the U.S. FK506 multicenter trial",
abstract = "In an effort to determine the total one-year cost of liver transplantation, the underlying drivers of that cost, and any cost differences between alternative immunosuppressive regimens, an analysis was performed comparing the average one-year posttransplant charges of 322 patients participating in the 'U.S. Multi-center Prospective Randomized Trial Comparing FK-506 to Cyclosporine in Liver Transplantation.' Total one-year inpatient charges including all readmissions were examined. Professional fees and outpatient charges were excluded. Costs for tacrolimus drug and blood assays were assumed to be equal to those in the CsA group. For patients completing the study, the tacrolimus group bad an average length of stay and average one-year cost seven days (P=.06) and $19,290 (P=.05) lower than the CsA group. The difference in rejection profiles between the two arms seems to largely account for the lower costs. The tacrolimus arm consistently had fewer patients in the more severe rejection groups. Increased incidence and severity of rejection were directly related to higher average lengths of stay and costs of transplantation (P < .001). Tacrolimus immunosuppression during the first year after liver transplantation is more cost-effective than CsA in achieving similar patient and graft survival rates. Differing incidence and severity of rejection can dramatically affect the first-year cost of liver transplantation.",
author = "Lake, {J. R.} and Gorman, {K. J.} and Esquivel, {C. O.} and Wiesner, {R. H.} and Klintmalm, {G. B.} and Miller, {C. M.} and Shaw, {B. W.} and Gordon, {J. A.}",
year = "1995",
language = "English (US)",
volume = "60",
pages = "1089--1095",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - The impact of immunosuppressive regimens on the cost of liver transplantation - Results from the U.S. FK506 multicenter trial

AU - Lake, J. R.

AU - Gorman, K. J.

AU - Esquivel, C. O.

AU - Wiesner, R. H.

AU - Klintmalm, G. B.

AU - Miller, C. M.

AU - Shaw, B. W.

AU - Gordon, J. A.

PY - 1995

Y1 - 1995

N2 - In an effort to determine the total one-year cost of liver transplantation, the underlying drivers of that cost, and any cost differences between alternative immunosuppressive regimens, an analysis was performed comparing the average one-year posttransplant charges of 322 patients participating in the 'U.S. Multi-center Prospective Randomized Trial Comparing FK-506 to Cyclosporine in Liver Transplantation.' Total one-year inpatient charges including all readmissions were examined. Professional fees and outpatient charges were excluded. Costs for tacrolimus drug and blood assays were assumed to be equal to those in the CsA group. For patients completing the study, the tacrolimus group bad an average length of stay and average one-year cost seven days (P=.06) and $19,290 (P=.05) lower than the CsA group. The difference in rejection profiles between the two arms seems to largely account for the lower costs. The tacrolimus arm consistently had fewer patients in the more severe rejection groups. Increased incidence and severity of rejection were directly related to higher average lengths of stay and costs of transplantation (P < .001). Tacrolimus immunosuppression during the first year after liver transplantation is more cost-effective than CsA in achieving similar patient and graft survival rates. Differing incidence and severity of rejection can dramatically affect the first-year cost of liver transplantation.

AB - In an effort to determine the total one-year cost of liver transplantation, the underlying drivers of that cost, and any cost differences between alternative immunosuppressive regimens, an analysis was performed comparing the average one-year posttransplant charges of 322 patients participating in the 'U.S. Multi-center Prospective Randomized Trial Comparing FK-506 to Cyclosporine in Liver Transplantation.' Total one-year inpatient charges including all readmissions were examined. Professional fees and outpatient charges were excluded. Costs for tacrolimus drug and blood assays were assumed to be equal to those in the CsA group. For patients completing the study, the tacrolimus group bad an average length of stay and average one-year cost seven days (P=.06) and $19,290 (P=.05) lower than the CsA group. The difference in rejection profiles between the two arms seems to largely account for the lower costs. The tacrolimus arm consistently had fewer patients in the more severe rejection groups. Increased incidence and severity of rejection were directly related to higher average lengths of stay and costs of transplantation (P < .001). Tacrolimus immunosuppression during the first year after liver transplantation is more cost-effective than CsA in achieving similar patient and graft survival rates. Differing incidence and severity of rejection can dramatically affect the first-year cost of liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0028839670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028839670&partnerID=8YFLogxK

M3 - Article

C2 - 7482713

AN - SCOPUS:0028839670

VL - 60

SP - 1089

EP - 1095

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 10

ER -